Bridging the Gap Between Dermatology and Gynecology for Menopausal and Perimenopausal Patients

BACKGROUND Menopause is a universal, multisystem physiologic transition affecting the integumentary, genitourinary, and many other organ systems. Dermatologists frequently encounter manifestations of genitourinary syndrome of menopause (GSM), yet these symptoms remain underrecognized, underdiagnosed, and undertreated. OBJECTIVE The aim of this article was to improve dermatologists' care of the perimenopausal and menopausal patients and strengthen collaboration with gynecology. MATERIALS AND METHODS A PubMed search was conducted through June 2026 using terms related to menopause, GSM, vulvovaginal symptoms, vaginal estrogen, and vulvar dermatoses. Relevant articles and professional society guidelines addressing the diagnosis and management of GSM and menopause-related care were reviewed . RESULTS GSM is diagnosed clinically, but symptoms may mimic, exacerbate, or coexist with inflammatory vulvar disease. Incorporating a structured menopause history into dermatologic evaluation improves recognition of overlapping conditions and guides referral or collaborative care. Low-dose vaginal estrogen is safe, first-line therapy for GSM, whereas other therapies, including energy-based devices, require cautious counseling given limited evidence. CONCLUSION GSM and its downstream effects are relevant to dermatologic care and may overlap with inflammatory, irritant, and neoplastic vulvar disease. Menopause-informed history taking, initiation of or referral for low-dose vaginal estrogen, and collaboration with gynecology can improve diagnosis and reduce fragmented care.